The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
 
Darren Cowzer
No Relationships to Disclose
 
Jessica B White
No Relationships to Disclose
 
Pin-Jung Chen
No Relationships to Disclose
 
Tae-Hyung Kim
No Relationships to Disclose
 
Danny Khalil
Consulting or Advisory Role - Abbvie; PsiOxus Therapeutics
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual property interests related to CD40, nanotechnology, and in situ vaccination.
 
Imane H. El Dika
Honoraria - Lynx Group
Consulting or Advisory Role - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Joanne F. Chou
No Relationships to Disclose
 
Amin Yaqubie
No Relationships to Disclose
 
Joseph S. Light
No Relationships to Disclose
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Hooman Yarmohammadi
No Relationships to Disclose
 
Joseph Patrick Erinjeri
Consulting or Advisory Role - AstraZeneca
 
Marinela Capanu
No Relationships to Disclose
 
Richard K. G. Do
Honoraria - ALK (I); Genentech (I)
Consulting or Advisory Role - Bayer; DBV Technologies (I); GE Healthcare
Patents, Royalties, Other Intellectual Property - UptoDate chapters on Food Allergy (I)
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Lilly; Pfizer; Scorpion Therapeutics; Syros Pharmaceuticals; Vividion Therapeutics
 
Ronak H. Shah
Stock and Other Ownership Interests - 10X Genomics; AstraZeneca/MedImmune; Guardant Health; Regeneron; Roche
 
Michael F. Berger
Consulting or Advisory Role - Lilly; PetDx
Research Funding - Grail
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); SOBI (I); Vector Health; Yiviva; Yiviva
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)
Travel, Accommodations, Expenses - Polaris
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Exelixis; Imvax; Lilly; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)